Multiple Myeloma [2017]: Bulletin #1
This edition presents key opinion leader (KOL) views on recent developments in the multiple myeloma (MM) market. Topics covered include; positive topline results from the Phase III study ALCYONE of Johnson & Johnson’s and Genmab’s Darzalex (daratumumab) in combination with Velcade (bortezomib; Takeda), melphalan and prednisone (VMP) versus VMP alone, as front-line treatment for newly diagnosed patients who are not considered candidates for autologous stem cell transplantation; BioLineRx’s initiation of Phase III trial GENESIS assessing BL-8040, a highly-selective antagonist of the CXCR4 chemokine receptor, for the mobilisation of haematopoietic stem cells for autologous transplantation in patients with multiple myeloma; Cellectar Biosciences’ announcement of encouraging results from Phase I trial investigating CLR 131 in patients with relapsed/refractory multiple myeloma.
Business Questions:
Business Questions:
- How does Johnson & Johnson’s and Genmab’s Darzalex compare to Empliciti (elotuzumab; Bristol Myers Squibb)?
- Is front-line treatment likely to be added to Darzalex’s label?
- Does data from ALCYONE support even broader use of Darzalex?
- How will varied use of the VMP regimen in Europe and North America affect the utilisation of Darzalex?
- Which patient types do KOLs expect to benefit from BioLineRx’s BL-8040?
- How does BL-8040 compare to Mozibil (plerixafor; Genzyme)?
- Is BL-8040 likely to demonstrate anti-tumour activity, and how will this affect commercial success?
- How do experts view early positive data for Cellectar Biosciences’ CLR 131?
- Do KOLs see a future for the drug conjugates approach in MM?
- What barriers to standard practice will radioactive drug conjugates face?
